Healthtech Late Stage Investors & VC Firms
494 firms in this list, with a median first check of $1M. 98 of them lead rounds. Generated from verified public data and updated continuously.
W Capital Partners
New YorkGrowth–Late Stage
21 people
Sozo Ventures
Redwood CityPre-Seed–Late Stage
29 people
S32
Palo AltoSeries A–Late Stage
30 people
NorthEdge
ManchesterGrowth–Late Stage$2.6M – $65M
34 people
Ireland Strategic Investment Fund
DublinSeed–Late Stage
Vensana Capital
MinneapolisSeries A–Late Stage
43 people
Platinum
Beverly HillsGrowth–Late Stage$100M – $10B
30 people
Impact Engine
ChicagoSeed–Late Stage$250K – $3M
25 people
Brentwood Associates
Los AngelesGrowth–Late Stage$50M – $200M
37 people
aMoon
Ra'ananaSeed–Late Stage
33 people
Blue Venture Funds
ChicagoSeed–Late Stage$1M – $20M
28 people
Lince Capital
LisbonSeed–Late Stage
36 people
Monozukuri Ventures
KyotoPre-Seed–Late Stage$100K – $300K
25 people
DAYLI Partners
SeoulSeed–Late Stage
13 people
Permira
St Peter PortSeries B–Late Stage
40 people
SJF Ventures
DurhamSeries A–Late Stage$1M – $10M
15 people
B4 Capital
Seed–Late Stage$10M – $50M
2 people
Cox Enterprises
AtlantaSeed–Late Stage
34 people
Cross Creek Advisors
Salt Lake CitySeries B–Late Stage
20 people
Avoro Capital Advisors
New YorkSeries A–Late Stage
22 people
Asahi Kasei Corporate Venture Capital
Menlo ParkPre-Seed–Late Stage$200K – $5M
25 people
Escalate Capital Partners
AustinGrowth–Late Stage
9 people
Boathouse Capital
BerwynGrowth–Late Stage$5M – $50M
17 people
BioGeneration Ventures
NaardenPre-Seed–Late Stage
26 people
Related lists
Healthtech Investors & VC Firms (4191)Healthtech Seed Investors & VC Firms (3233)Healthtech Investors & VC Firms in North America (2666)Healthtech Investors & VC Firms in United States (2437)Healthtech Series A Investors & VC Firms (2310)Late Stage Investors & VC Firms (1725)Healthtech Pre-Seed Investors & VC Firms (1468)Healthtech Investors & VC Firms in Europe (1358)Healthtech Growth Investors & VC Firms (1270)Healthtech Investors & VC Firms in Global (1182)
Data sourced from public filings and firms' own websites — see our methodology.




































































































